Minerva Neurosciences Priced, Nasdaq: NERV
Clinical-stage biotech developing treatments for central nervous system diseases.
Industry: Health Care
First Day Return: +0.8%
Industry: Health Care
NERV
Clinical-stage biotech developing treatments for central nervous system diseases.
| IPO Data | |
|---|---|
| IPO File Date | 04/09/2014 |
| Offer Price | $6.00 |
| Price Range $6.00 - $6.00 | |
| Offer Shares (mm) | 5.5 |
| Deal Size ($mm) | $33 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 06/30/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $33 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Cambridge, MA, United States |
| Founded | 2007 |
| Employees at IPO | 6 |
| Website www.minervaneurosciences.com | |
IPO News for Minerva Neurosciences
Minerva Neurosciences (NERV) Performance
